ArticleJournal for immunotherapy of cancer2021
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma.
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis.Blood advances · 2026Article
- B -Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor- T -Cell Therapy for Relapsed or Refractory AL Amyloidosis.Journal of the American Society of Nephrology : JASN · 2026Article
- Delayed kidney response in AL amyloidosis: prevalence and clinical significance.Clinical kidney journal · 2026Article
- The Evolving Landscape of Anti-Clonal Therapy in Newly Diagnosed Systemic Light-Chain (AL) Amyloidosis: Evidence- and Time-Based Comparison with Multiple Myeloma.Life (Basel, Switzerland) · 2026Review
- AL amyloidosis: a real-world experience with CAR T-cell therapy.Blood advances · 2026Article
- In vivo chimeric antigen receptor (CAR)-T cell therapy.Nature reviews. Drug discovery · 2026Review
- CAR-T cell therapy in nephrology.Renal failure · 2025Review
- A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review.International journal of hematology · 2025Review
- BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis.Current oncology (Toronto, Ont.) · 2025Review
- Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature.Acta haematologica · 2025Review
- Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.Frontiers in immunology · 2025Review
- Uncovering the knowledge about systemic amyloidosis relevant to the rheumatologists.Advances in rheumatology (London, England) · 2024Review
- Review
- Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.Journal of clinical medicine · 2024Review
- B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.ESC heart failure · 2024Article
- Current progress in CAR-based therapy for kidney disease.Frontiers in immunology · 2024Review
- Treatment of AL amyloidosis in the era of novel immune and cellular therapies.Frontiers in oncology · 2024Review
- First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma.EJHaem · 2023Article
- Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety.Current oncology (Toronto, Ont.) · 2023Article
- The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.BMC cancer · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
28 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) remains incurable despite the number of novel therapies that have become available in recent years. Occasionally, a patient with MM will develop an amyloid light-chain (AL) amyloidosis with organ dysfunction. Chimeric antigen receptor T-cell (CART) therapy has become a promising approach in treating hematological malignancies. Our institution has developed a second-generation B-cell maturation antigen (BCMA)-CART which is currently being tested in a clinical trial for relapsed/refractory MM.We present the first reported case, to our knowledge, of a patient with AL amyloidosis and renal involvement in the course of an MM, successfully treated with CART therapy targeting BCMA. The patient received a fractioned dose of 3×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.